Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's Disease

被引：4

作者：

Papamichael, Konstantinos ^{[1
]}

Dubinsky, Marla C. ^{[2
]}

Cheifetz, Adam S. ^{[1
]}

机构：

[1] Harvard Med Sch, Ctr Inflammatory Bowel Dis, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02115 USA

[2] Icahn Sch Med Mt Sinai, Div Gastroenterol, New York, NY USA

来源：

GASTROENTEROLOGY | 2023年 / 164卷 / 01期

关键词：

BIOLOGICS;

D O I：

10.1053/j.gastro.2022.04.014

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：164 / 165

页数：2

共 50 条

[31] Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn's disease patients
Liefferinckx, C.
Fassin, M.
Thomas, D.
Minsart, C.
Cremer, A.
Amininejad, L.
Tafciu, V.
Wambacq, V.
Van Gossum, A.
Franchimont, D.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S331 - S333
[32] Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
Choi, So Yoon
Choi, Young Ok
Choe, Yon Ho
Kang, Ben
JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (16)
[33] Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in paediatric Crohn's disease patients
Kang, B.
Lee, K.
Choe, B. -H.
Choe, Y. H.
JOURNAL OF CROHNS & COLITIS, 2017, 11 : S424 - S425
[34] Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort
Negoescu, Diana M.
Enns, Eva A.
Swanhorst, Brooke
Baumgartner, Bonnie
Campbell, James P.
Osterman, Mark T.
Papamichael, Konstantinos
Cheifetz, Adam S.
Vaughn, Byron P.
INFLAMMATORY BOWEL DISEASES, 2020, 26 (01) : 103 - 111
[35] Proactive therapeutic drug monitoring of anti-TNF agents is associated with higher mucosal healing rates in Crohn's disease
Brinar, M.
Sabic, M.
Turk, N.
Grgic, D.
Domislovic, V.
Cavka, S. Cukovic
Kozmar, A.
Krznaric, Z.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S506 - S506
[36] Proactive therapeutic drug monitoring is not associated with lower rates of steroid exposure or excess in adalimumab treated IBD patients
Sartain, Stephanie
Al-Ezairej, Maryam
Cummings, Fraser
Wootton, Stephen
GUT, 2023, 72 (SUPPL_2) : A111 - A111
[37] Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab
Cherry, Mohamad
Dutzer, Dominique
Nasser, Yara
Berger, Anne-Emmanuelle
Roblin, Xavier
Paul, Stephane
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 10
[38] Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohn's Disease
Lie, Mitchell R. K. L.
Kreijne, Joany E.
van der Woude, C. Janneke
INFLAMMATORY BOWEL DISEASES, 2017, 23 (01) : 75 - 81
[39] Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease
Wright, Emily K.
Kamm, Michael A.
De Cruz, Peter
Hamilton, Amy L.
Selvaraj, Fabiyola
Princen, Fred
Gorelik, Alexandra
Liew, Danny
Prideaux, Lani
Lawrance, Ian C.
Andrews, Jane M.
Bampton, Peter A.
Jakobovits, Simon L.
Florin, Timothy H.
Gibson, Peter R.
Debinski, Henry
Macrae, Finlay A.
Samuel, Douglas
Kronborg, Ian
Radford-Smith, Graham
Gearry, Richard B.
Selby, Warwick
Bell, Sally J.
Brown, Steven J.
Connell, William R.
JOURNAL OF CROHNS & COLITIS, 2018, 12 (06): : 653 - 661
[40] Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease
Papamichael, Konstantinos
Juncadella, Anna
Wong, Danny
Rakowsky, Shana
Sattler, Lindsey A.
Campbell, James P.
Vaughn, Byron P.
Cheifetz, Adam S.
JOURNAL OF CROHNS & COLITIS, 2019, 13 (08): : 976 - 981

← 1 2 3 4 5 →